Opinion|Videos|September 27, 2024
Established Multidisciplinary Therapies for SCLC
Panelists discuss how conventional therapies for extensive-stage and limited-stage small cell lung cancer (SCLC) have evolved, including the role of chemoradiotherapy (CRT) and its various schedules, while exploring unmet needs in extensive-stage settings and the potential for combining immunotherapies with CRT to improve treatment outcomes.
Advertisement
Episodes in this series
- What are the conventional therapies that have been used to treat extensive-stage (small cell lung cancer) SCLC and what has their data shown?
a. What are the current unmet needs in extensive-stage settings?
- What are the therapies used for limited-stage SCLC and what is the role of chemoradiotherapy (CRT), and what has the data shown?
a. What are the differences between the schedules of CRT, eg, daily/twice daily/sequential?
- Do you see opportunities in building upon CRT as a standard of care by including systemic therapies, such as immunotherapies, in combination?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Moderna’s mRNA Flu Vaccine After Phase 3 Success
2
CANN Responds to HRSA's Revised 340B Rebate Model Pilot
3
Setting Treatment Goals in RA: Remission, Joint Damage, and Systemic Risk
4
Predicting GLP-1 Discontinuation From Pharmacy Claims
5